lung cancer

[Cell Death Discovery] The authors focus on the function of lncRNAs in programmed cell death (PCD) of NSCLC and summarize the therapeutic role of targeting lncRNAs in PCD for NSCLC treatment

[Genprex, Inc.] Genprex, Inc. announced the opening for patient enrollment of its Acclaim-2 clinical trial, an open-label, multi-center Phase I/II clinical trial evaluating the Company’s lead drug candidate, REQORSA™ Immunogene Therapy, in combination with Keytruda® in patients with late-stage non-small cell lung cancer whose disease progressed after treatment with Keytruda.

[Cell Death & Disease] Investigators found that tripartite motif (TRIM) 46 promoted lung adenocarcinoma cell proliferation and cisplatin resistance by enhancing glycolysis.

[Cell Death Discovery] The authors demonstrated that HORMAD1 promotes the proliferation, migration and invasion of lung cancer cells both in vitro and in vivo by inducing epithelial–mesenchymal transition.

[Bioengineered] Researchers explored the potential mechanism of exosome-derived miR-631 targeting and regulating E2F family of transcription factor 2 to repress the malignant behavior of NSCLC cells.

[Thoracic Cancer] Inhibition of progression of lung cancer cells induced by heterogeneous nuclear ribonucleoprotein K-knockdown was dependent on activation of p53 by the p53/p21/cyclin D1 pathway.